1. Home
  2. BIRD vs MRKR Comparison

BIRD vs MRKR Comparison

Compare BIRD & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allbirds Inc.

BIRD

Allbirds Inc.

HOLD

Current Price

$3.99

Market Cap

26.2M

ML Signal

HOLD

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

HOLD

Current Price

$1.40

Market Cap

27.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BIRD
MRKR
Founded
2015
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.2M
27.7M
IPO Year
2021
2010

Fundamental Metrics

Financial Performance
Metric
BIRD
MRKR
Price
$3.99
$1.40
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
$8.00
$10.00
AVG Volume (30 Days)
1.1M
60.5K
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
20.22
33.61
EPS
N/A
N/A
Revenue
$152,466,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$35.12
$936.27
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.15
$0.81
52 Week High
$24.31
$4.07

Technical Indicators

Market Signals
Indicator
BIRD
MRKR
Relative Strength Index (RSI) 39.09 45.74
Support Level $3.85 $1.34
Resistance Level $4.55 $1.52
Average True Range (ATR) 0.47 0.07
MACD -0.34 -0.01
Stochastic Oscillator 4.61 21.74

Price Performance

Historical Comparison
BIRD
MRKR

About BIRD Allbirds Inc.

Allbirds Inc is a lifestyle brand that innovates with naturally derived materials to make footwear and apparel products in a better way, while treading lighter on the planet. Its primary source of revenue is from sales of shoes and apparel products. The majority of the revenue is derived from United States.

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: MT-601; and MT-401-OTS.

Share on Social Networks: